Business, energy, technology, markets and global industry news from Business News Today

CAMCEVI

PharmaDeviceNews CAMCEVI
Representative image showing a prostate cancer research and testing environment, aligned with our coverage of Rubraca’s FDA approval and its Phase 3 TRITON3 trial results in BRCA-mutated metastatic castration-resistant prostate cancer.
Pharma & Biotech

China approves Foresee’s twice-yearly prostate cancer injection. Could it unlock a $123.85m milestone deal?

Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.

Read More
Pharma & Biotech

Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe

CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.

Read More